We’ve become remarkably good at reading cancer cells. Spatial biology enabled us to read them in context. Today we discuss a new Nature study suggesting that the tumor microenvironment—the immune cells, stromal cells, and surrounding biology that often determines whether a therapy succeeds or fails—can be measured from a simple blood draw, or liquid biopsy.
To do that we’re joined by Dr. Vincent Miller, an oncologist and former founding Chief Medical Officer of Foundation Medicine, and Dr. Mirna Jarosz, CEO of LiquidCell Dx.
The work introduces a striking idea. Rather than focusing only on mutations inside tumor cells, it identifies recurring spatial ecosystems within tumors and then shows that their signatures can be recovered from plasma cell-free DNA using methylation patterns. The implication is that liquid biopsy may soon reveal not only what mutations a tumor carries, but how its surrounding biology is organized before treatment ever begins.
But wait. How can blood possibly contain information about spatial organization inside a tumor? That answer unfolds gradually on today’s show, making the final portion of the discussion particularly rewarding.
As Jarosz explains, “We’ve condensed spatial biology to really critical and recurring biological programs. And then we can measure those in blood. So now we have that spatial insight of the tumor microenvironment in a liquid biopsy.”
For Miller, the significance is ultimately clinical. “The tumor is almost like an organ,” he says. “The ability to understand how that organ is constructed and what structures are near one another and how they’re functioning... is really the underpinning” of why patients with seemingly similar cancers can have dramatically different responses to therapy.
If this approach continues to hold up in larger clinical studies, liquid biopsy may expand from reading the genetics of cancer to reading its ecosystem. This shift could improve immunotherapy selection, longitudinal monitoring, and our understanding of cancer biology itself.
